Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2234 total matches.
Intravenous Diclofenac (Dyloject)
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
has been shown to reduce opioid
use and the incidence of opioid-related adverse
effects.1 Administration ...
The FDA has approved Dyloject (Hospira), an IV
formulation of the NSAID diclofenac sodium, for use
in adults. It can be administered alone for treatment
of mild to moderate pain or in combination with opioid
analgesics for moderate to severe pain. Dyloject is the
first injectable formulation of diclofenac to become
available in the US.
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
death receptor-1 (PD-1) blocking
antibody nivolumab (Opdivo)1 and the anti-CLA-4
antibody ipilimumab ...
The FDA has approved the combined use of the
programmed death receptor-1 (PD-1) blocking
antibody nivolumab (Opdivo) and the anti-CLA-4
antibody ipilimumab (Yervoy) for treatment of BRAF
V600 wild-type unresectable or metastatic melanoma.
This is the first immunotherapy combination to be
approved for treatment of any type of cancer.
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third longacting
human insulin ...
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by the
FDA; insulin detemir (Levemir) and insulin glargine
(Lantus, Toujeo) were approved earlier.
Ferric Citrate (Auryxia) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
Exams
Published by The Medical Letter, Inc. • A Nonprofit Organization
Table 1. Some Oral Drugs ...
The FDA has approved ferric citrate (Auryxia –
Keryx), an oral phosphate binder, for treatment of
hyperphosphatemia in patients with chronic kidney
disease (CKD) on dialysis. It is the second iron-based
phosphate binder to be approved in the US, and the
first that causes significant systemic absorption of
iron. Auryxia is not FDA-approved for treatment of
iron deficiency anemia.
Deoxycholic Acid (Kybella) for Double Chin
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
.1 Kybella contains synthetically derived
deoxycholic acid. When the drug is injected ...
The FDA has approved the use of subcutaneous
injections of deoxycholic acid (Kybella – Kythera/Allergan) to improve the appearance of moderate
to severe convexity or fullness associated with submental
fat (double chin) in adults. It is the first drug
approved for this indication.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
dabigatran etexilate (Pradaxa).1 Idarucizumab is the
first specific reversal agent to become available ...
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is the
first specific reversal agent to become available for
one of the new oral anticoagulants.
Bexsero - A Second Serogroup B Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
. It is the second serogroup B meningococcal vaccine
to be approved in the US; Trumenba was the first.1
Both ...
The FDA has approved Bexsero (Novartis/GSK), a
vaccine that protects against invasive meningococcal
disease caused by Neisseria meningitidis serogroup
B. It is the second serogroup B meningococcal vaccine
to be approved in the US; Trumenba was the first.
Both vaccines are approved for use in persons 10-25
years old. Bexsero is approved in Europe, Canada, and
Australia for use in children as young as 2 months old.
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)1 ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...
In Brief: Technivie for HCV Genotype 4 Infection (online only)
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
as Viekira Pak for treatment
of HCV genotype 1 infection.1
HCV genotype 4 is uncommon in the US and Canada ...
The FDA has approved Technivie (Abbvie), a fixed-dose combination of the direct-acting antiviral agents ombitasvir and paritaprevir and the pharmacokinetic enhancer ritonavir, for oral treatment of chronic hepatitis C virus (HCV) genotype 4 infection in patients without cirrhosis. It is indicated for use in combination with ribavirin. Ombitasvir/paritaprevir/ritonavir copackaged with dasabuvir, an HCV RNA polymerase inhibitor that has little activity against HCV genotype 4, is approved as Viekira Pak for treatment of HCV genotype 1 infection.1HCV genotype 4 is uncommon in the US and Canada. It...
Cobicistat (Tybost) and Combinations for HIV
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
(Prezcobix — Janssen) for treatment of
HIV-1 infection. Both atazanavir and darunavir have
traditionally ...
Cobicistat, a pharmacokinetic enhancer that boosts
levels of some HIV drugs but has no antiretroviral
activity of its own, is now available alone as Tybost
(Gilead) and in fixed-dose combinations with the
protease inhibitors atazanavir (Evotaz — BMS) and
darunavir (Prezcobix — Janssen) for treatment of
HIV-1 infection. Both atazanavir and darunavir have
traditionally been used in combination with the
CYP3A inhibitor ritonavir (Norvir) to boost their serum
concentrations, but neither is available in a fixed-dose
combination with ritonavir.